Home / Psoriasis (page 2)


Here you will find the latest clinical research on psoriasis.

Longer Psoriasis Duration May Mean Higher CVD Risk


Duration of mild or moderate psoriasis had an influence on the risk of major acute coronary events (MACE) over time, a cohort and population study together showed. Based on imaging study results and observational registry data, investigators found that for each additional year of disease duration, there was a 1% …

Read More »

Risk of uncommon cancers in patients with psoriasis

psoriasis cancer risk

Abstract Background Cancer-associated mortality is increased in psoriasis. However, little is known about the risk of less common cancers. Objective We aimed to evaluate the risk of less common cancers in patients with psoriasis compared to persons without psoriasis using a nationwide cohort study. Methods Between January 1st 2008 and December …

Read More »

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care


Abstract Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe psoriasis. However, as per study protocols, transition periods from prior psoriasis treatments of a defined minimal length were required and use of concomitant psoriasis medication was prohibited. There is therefore …

Read More »

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis


Background EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. Objective To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product …

Read More »

How Safe Are Various Systemic Therapies for Pediatric Psoriasis?

Pediatric Psoriasis

NEW YORK (Reuters Health) – For children with psoriasis, adverse events (AEs) occur less frequently with tumor necrosis factor (TNF) inhibitors than with methotrexate, but appropriate folic acid administration may mitigate the latter’s gastrointestinal effects, researchers suggest. “Our understanding of the immune changes in skin that lead to psoriasis has …

Read More »

Association between circulating prolactin levels and psoriasis and its correlation with disease severity: A meta-analysis


Lee YH, et al. – The correlation between circulating prolactin (PRL) levels and psoriasis, and between serum/plasma PRL levels and psoriasis severity was comprehensively assessed in this trial. Higher circulating PRL levels were discovered in patients with psoriasis. It was inferred that PRL levels could associate with psoriasis severity. Methods …

Read More »